{"filings":[{"id":95145,"accession_number":"0001193125-26-210299","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Therapeutics Reports Q1 2026 Results; BEAM-302 Pivotal Cohort and Risto-cel BLA on Track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["BEAM-302 Phase 1/2 data showed single-dose safety and efficacy; 60 mg selected as optimal dose; global pivotal cohort to start H2 2026.","Risto-cel (BEAM-101) Phase 1/2 data published in NEJM; BLA submission expected as early as year-end 2026 for sickle cell disease.","Cash, cash equivalents and marketable securities were $1.2 billion as of March 31, 2026; cash runway into mid-2029.","Net loss of $94.3 million ($0.91 per share) for Q1 2026, compared to net loss of $108.3 million ($1.23 per share) in Q1 2025.","IND filing for BEAM-304 in PKU and initial data for BEAM-301 in GSDIa expected in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":31738000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108006,"accession_number":"0001193125-26-093914","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Beam terminates license pact with Bio Palette; Kobe University standby license activated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mutual termination of License Agreement with Bio Palette effective March 2, 2026 due to Bio Palette's planned dissolution.","Standby License Agreement with Kobe University activated, granting Beam exclusive license to base editing patents previously covered.","No future payments due between Beam and Bio Palette under the Termination Agreement or License Agreement.","Beam retains rights to exploit base editing technology for human disease worldwide, minus microbiome field in Asia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108005,"accession_number":"0001193125-26-065191","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"Beam Q4 net income $244.3M (full-year loss $80.0M); new PKU program; $500M Sixth Street credit facility","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net income $244.3M ($2.33 diluted EPS); full-year net loss $80.0M ($0.81 per share).","New liver-targeted program BEAM-304 for PKU; IND filing expected in 2026; targets two most prevalent PAH mutations.","$500M senior secured credit facility with Sixth Street; $100M funded at close; additional draws tied to risto-cel milestones.","Cash, cash equivalents and marketable securities $1.25B as of Dec 31, 2025; runway into mid-2029 with Sixth Street capital.","Risto-cel BLA submission expected as early as year-end 2026; BEAM-302 FDA alignment on accelerated approval path."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":139743000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108004,"accession_number":"0001193125-26-048684","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Beam Therapeutics secures standby direct license to Kobe University patents for base editing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement dated Feb 9, 2026 among Beam, Bio Palette, and Kobe University ensures backup patent access.","If Kobe-Bio Palette license terminates (barring Beam-caused breach), Kobe grants Beam an exclusive direct license.","Beam will pay Kobe the same amounts it would have paid Bio Palette under the original sublicense.","Beam assumes prosecution and maintenance costs for Kobe patents after the effective time.","Standby license covers the same scope as Beam's current sublicense from Bio Palette."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108003,"accession_number":"0001193125-26-039365","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Carole Ho resigns from Beam Therapeutics board effective Feb 27, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carole Ho notified resignation on Jan 31, 2026, effective Feb 27, 2026.","Resignation not due to any disagreement with Beam on operations, policies, or practices.","No successor or replacement director announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108002,"accession_number":"0001193125-26-009722","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Beam reports $1.25B cash, FDA alignment on BEAM-302 accelerated path; risto-cel BLA expected year-end 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Estimated $1.25B cash, cash equivalents and marketable securities as of Dec 31, 2025; operating runway extended into 2029.","FDA alignment on potential accelerated approval for BEAM-302 based on AAT biomarkers over 12 months; ~50 additional patients to be enrolled.","BLA submission for risto-cel (formerly BEAM-101) expected as early as year-end 2026; BEACON trial fully enrolled, manufacturing done December 2025.","Updated BEAM-302 Phase 1/2 data and pivotal plan expected by end of Q1 2026; new liver-targeted program to be announced H1 2026.","Initial BEAM-301 clinical data expected in 2026; BEAM-103 Phase 1 healthy volunteer trial to complete dosing in H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124417,"accession_number":"0001193125-25-316043","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["2.01"],"status":"ready","headline":"Beam Therapeutics nets $255.1M cash from sale of Orbital stake in BMS acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Beam received $255.1M in closing cash plus up to ~$26.3M from escrow for its 75M shares (17% fully diluted) of Orbital.","Bristol-Myers Squibb completed acquisition of Orbital on December 8, 2025, triggering the payout.","Beam to update cash runway guidance at the 2026 J.P. Morgan Healthcare Conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124416,"accession_number":"0001193125-25-263536","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Q3 net loss $112.7M; cash $1.1B; BEAM-302 expands; Orbital acquisition by BMS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $112.7M ($1.10 per share) in Q3 2025 vs $96.7M ($1.17 per share) in Q3 2024.","Cash, cash equivalents and marketable securities $1.1B as of Sep 30, 2025, up from $850.7M at Dec 31, 2024; runway into 2028.","BEAM-302 expanded: multi-dose cohort (60 mg x2, 8 wks apart) in Part A; first patient dosed in Part B (liver disease). Data in early 2026.","BEAM-101 updated data accepted for ASH Dec 2025; FDA granted RMAT designation in Aug 2025.","First subject dosed with BEAM-103 (ESCAPE mAb) in Phase 1 HV trial; BMS to acquire Orbital for $1.5B; Beam holds ~17% stake."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":25634000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141086,"accession_number":"0000950170-25-102389","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Q2 net loss $102.3M; cash $1.2B; BEAM-302 17 patients dosed; BEAM-101 enrollment complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $102.3M ($1.00/share) vs $91.1M loss ($1.11/share) in Q2 2024; R&D expense rose to $101.8M.","Cash, cash equivalents and marketable securities $1.2B as of June 30, 2025; runway into 2028.","BEAM-302 Phase 1/2: 17 patients dosed; expanded dose exploration underway; Part B enrollment initiated; data expected early 2026.","BEAM-101 BEACON trial: 30 SCD patients dosed (adults + first adolescent); updated data expected by end of 2025.","FDA granted orphan drug designation for BEAM-101 and BEAM-302, and RMAT designation for BEAM-302."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":15936000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141085,"accession_number":"0000950170-25-093906","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Beam Therapeutics acquires early-stage life sciences company for 403k shares plus up to $89M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront consideration: 403,128 shares of BEAM common stock (~$6.86M based on $17.01 close).","Earnout: up to $89M in development, clinical, and commercial milestones, payable in cash or stock at Beam's discretion.","If milestones paid in stock, maximum issuable shares ~5.23M based on $17.01 closing price.","Shares issued as unregistered securities under Section 4(a)(2) exemption.","Target is an early-stage life sciences company; name not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158889,"accession_number":"0000950170-25-083043","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Beam Therapeutics shareholders elect directors, ratify Deloitte, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Mark Fishman (61.9M for, 10.3M against), Carole Ho (71.7M for), and Kathleen Walsh (71.9M for) as Class II directors.","Ratified Deloitte & Touche as independent auditor for FY2025 with 84.3M for, 154K against, 63.6K abstentions.","Advisory vote on named executive officer compensation approved: 71.7M for, 562.9K against, 33.9K abstentions.","All proposals passed; broker non-votes were 12.2M on director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158888,"accession_number":"0000950170-25-063955","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Q1 net loss $109.3M; cash $1.2B after $500M financing; clinical milestones hit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $109.3M ($1.24/share) vs $98.7M ($1.21/share) Q1 2024; R&D spend $98.8M.","Cash $1.2B including $500M financing; runway into 2028.","First patient dosed for BEAM-301 in GSDIa; IND cleared for BEAM-302 in AATD.","BEAM-101 updated data accepted at EHA June 2025; aim to dose 30 SCD patients by mid-2025.","BEAM-302 fourth cohort dosing started; further data expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":7470000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177291,"accession_number":"0001193125-25-051072","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Beam prices $500M underwritten offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten offering of 16,151,686 shares at $28.48 per share and pre-funded warrants for 1,404,988 shares at $28.47 each.","Gross proceeds ~$500.0M; net proceeds after discounts and expenses ~$469.7M.","Use of proceeds: platform technology, R&D for BEAM-101, BEAM-302 pivotal trial, ESCAPE conditioning trial, general corporate.","Closing expected March 11, 2025; J.P. Morgan, Jefferies, Cantor, Citigroup, Wells Fargo as joint bookrunners.","Pre-funded warrants exercisable immediately at $0.01 per share, with cashless exercise and beneficial ownership limitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177290,"accession_number":"0001193125-25-050334","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Beam reports positive initial Phase 1/2 data for BEAM-302 in AATD; total AAT exceeds protective threshold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BEAM-302 well tolerated at all doses; no serious AEs or dose-limiting toxicities observed.","Single 60 mg dose achieved mean total AAT of 12.4 µM at Day 28, exceeding 11 µM protective threshold.","Mutant Z-AAT reduced up to 78% from baseline at 60 mg dose level.","First clinical evidence of precise genetic correction of a disease-causing mutation via base editing.","Dose escalation to continue; further data expected at medical conference in H2 2025; Part B dosing planned H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177289,"accession_number":"0000950170-25-026070","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Therapeutics reports Q4 net loss of $90.4M; cash $850.7M, clinical milestones reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share $1.09 in Q4 2024 vs net income of $1.77 in Q4 2023; full-year net loss $4.58 per share vs $1.72 in 2023.","Cash, equivalents and marketable securities $850.7M at Dec 31, 2024, expected to fund operations into 2027.","Adult enrollment target achieved in BEACON trial of BEAM-101; updated data and 30 patients dosed expected by mid-2025.","Initial data from BEAM-302 Phase 1/2 in alpha-1 antitrypsin deficiency expected in H1 2025; BEAM-301 dosing to start early 2025.","Appointed Sravan Emany as CFO; Chirfi Guindo to board; IND-enabling studies for ESCAPE conditioning ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":63518000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177288,"accession_number":"0000950170-25-004558","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Beam Therapeutics: $850.7M cash, pipeline progress, 2025 catalysts detailed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, equivalents and marketable securities of $850.7M as of Dec 31, 2024; runway now into 2027 including BEAM-101 commercial readiness.","More than 40 adult SCD patients enrolled in BEACON trial; Beam expects to dose 30 patients and present updated data by mid-2025.","Initial Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency expected in first half 2025.","BEAM-301 Phase 1/2 trial in GSD1a: first site active, dosing to commence in early 2025.","ESCAPE nongenotoxic conditioning IND-enabling studies underway; BEAM-103 healthy volunteer study expected by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194051,"accession_number":"0001193125-24-272860","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Beam reports BEAM-101 Phase 1/2 data: all 7 patients achieved >60% HbF, resolved anemia; ESCAPE proof-of-concept in NHPs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Seven patients dosed with BEAM-101 achieved HbF >60%, HbS <40%, and resolution of anemia; no VOCs post-engraftment.","Mean neutrophil engraftment 17.1 days, platelet 19.1 days; one death from busulfan-related respiratory failure deemed unrelated.","ESCAPE antibody conditioning in NHPs enabled long-term engraftment of base-edited HSCs with >80% HbF-containing cells.","BEAM-103 mAb dosing was well tolerated without transfusions or supportive care; minor declines in neutrophils/platelets.","BEAM-302 initial clinical data from multiple cohorts now expected in first half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194050,"accession_number":"0001193125-24-271965","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Beam Therapeutics appoints Sravan Emany as CFO effective Dec 19, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sravan Emany previously CFO/COO of Ironwood Pharmaceuticals; also held roles at Integra, Bank of America, Goldman Sachs.","Annual base salary of $575,000; sign-on bonus of $325,000; target annual incentive bonus of 50% of salary.","Granted incentive stock option for 160,000 shares and restricted stock units for 80,000 shares, both vesting over four years.","Under the offer letter, severance includes 12 months base salary and COBRA premiums if terminated without cause.","Appointment effective December 19, 2024; Emany will serve as principal financial officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194049,"accession_number":"0001193125-24-270314","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Beam Therapeutics appoints Chirfi Guindo to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chirfi Guindo, chief marketing officer of Human Health at Merck, appointed to Beam's board.","Board expanded from seven to eight members; Guindo elected as Class I director effective Dec. 2, 2024.","Guindo brings 25+ years at Merck and Biogen, expertise in global strategy and commercial operations.","He will serve on the Compensation Committee of the board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194048,"accession_number":"0000950170-24-121099","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Beam reports initial BEAM-101 clinical data: engraftment, HbF >60%, one death from busulfan conditioning","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BEAM-101 (sickle cell disease): 4 patients engrafted, median 17 days neutrophil, 20 days platelet; HbF >60% by month 1.","BEAM-101: One death from respiratory failure attributed to busulfan conditioning, not BEAM-101; DSMC and FDA reviewed.","BEAM-201 (T-ALL/T-LL): 2 of 3 patients achieved CRi/CR at doses <200 million cells; both eligible for stem cell transplant.","ESCAPE NHP data: CD117 mAb conditioning well tolerated; HbF reached ~85% F-cells by 35 weeks in both animals.","Initial data from BEACON trial also showed no VOCs post-treatment and normalization of hemolysis markers in all 4 evaluable patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194047,"accession_number":"0000950170-24-121088","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Beam Therapeutics discusses Q3 results and ASH abstracts on investor call","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Investor presentation covered Q3 financial results, but no specific figures provided in filing.","Presented preclinical and clinical data from ASH abstracts, including ESCAPE and BEAM-101.","Company reiterated sickle cell disease strategy and provided business update."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":33451000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194046,"accession_number":"0000950170-24-121069","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Therapeutics Q3 net loss $96.7M; cash $925.8M; BEAM-101 enrollment at 35 patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $96.7M ($1.17/share) vs $96.1M ($1.22) Q3 2023; R&D $94.3M, G&A $26.5M.","Cash, equivalents, and marketable securities $925.8M as of Sep 30, 2024; runway into 2027.","BEACON trial of BEAM-101: 35 patients enrolled, 8 dosed in sickle cell disease; ASH data Dec 2024.","First cohort dosing complete for BEAM-302 in alpha-1 antitrypsin deficiency; initial data expected 2025.","ESCAPE platform (BEAM-103/104) nominated for development in SCD and beta-thalassemia."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":33451000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210380,"accession_number":"0000950170-24-091201","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Therapeutics Q2 net loss $91.1M; cash $1.0B; BEAM-101 enrollment tops 20, six dosed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss widened to $91.1M ($1.11/shr) from $82.8M ($1.08/shr) in Q2 2023.","Cash, cash equivalents and marketable securities $1.0B at June 30 vs $1.2B at Dec 31, 2023.","BEAM-101 Phase 1/2 BEACON trial: >20 patients enrolled, 6 dosed; initial data submitted for ASH.","FDA cleared IND for BEAM-301 (GSDIa); patient dosing expected in early 2025.","First patient dosed in BEAM-302 Phase 1/2 trial (AATD); initial clinical data expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":19182000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210379,"accession_number":"0001193125-24-178824","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Beam Therapeutics CFO Terry-Ann Burrell resigns; CEO John Evans named interim principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Terry-Ann Burrell resigns effective Aug 9, 2024 to join JPMorgan as vice chairman of investment banking.","CEO John Evans appointed Principal Financial and Accounting Officer upon her departure, continuing as CEO.","Company initiates search for a permanent CFO successor.","Burrell had served as CFO for 5 years, overseeing IPO and capital raising efforts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228700,"accession_number":"0000950170-24-071345","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Beam Therapeutics shareholders elect Graham Cooper as Class I director, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Graham Cooper elected to board with 49.5M for, 6.5M against, 1.8M abstain, 8.4M broker non-votes.","Deloitte & Touche ratified as auditor for FY2024: 66.0M for, 176k against, 42k abstain.","Advisory vote on executive compensation passed: 56.5M for, 1.3M against, 45k abstain, 8.4M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228699,"accession_number":"0000950170-24-053928","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Therapeutics Q1 net loss $98.7M; BEAM-101 expansion cohort opened, cash $1.1B into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $98.7M ($1.21 per share) vs $96.5M ($1.33 per share) in Q1 2023.","Cash, cash equivalents and marketable securities $1.1B as of March 31, 2024; runway into 2027.","R&D expenses $84.8M, G&A expenses $26.7M for Q1 2024.","BEAM-101 BEACON trial sentinel cohort dosing completed; expansion cohort initiated with up to 45 patients.","BEAM-302 CTA cleared in UK for Phase 1/2 in AATD; BEAM-301 IND submission on track for H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":7410000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}